Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Core Viewpoint - Emergent BioSolutions has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax in 2026 under an existing IDIQ contract [1] Group 1: Contract Details - The order includes a one-year base period with two additional option periods for 2027 and 2028 [2] - Deliveries under this order will take place in 2026 [2] Group 2: Product Information - BioThrax is indicated for the active immunization against disease caused by Bacillus anthracis in individuals aged 18 to 65 [3] - The vaccine is approved for both pre-exposure and post-exposure prophylaxis of anthrax [3] Group 3: Company Mission - Emergent BioSolutions aims to protect and save lives, focusing on health threats such as anthrax, smallpox, and Ebola [6]